Meeting
2021 ASCO Annual Meeting
Bone safety profile of steroidal aromatase inhibitor in comparison to non-steroidal aromatase inhibitors in postmenopausal women with breast cancer: A network meta-analysis.
Authors
Shanshan Chen
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Shanshan Chen , Bo Lan , Dan Lv , Fei Ma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 527)
DOI
10.1200/JCO.2021.39.15_suppl.527
Abstract #
527
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy and safety of initial five years of adjuvant endocrine therapy in postmenopausal hormone receptor-positive breast cancer: A systematic review and network meta-analysis.
First Author: Hao Liao
Poster
2021 ASCO Annual Meeting
Associations between preexisting nociplastic pain and early discontinuation of aromatase inhibitor therapy in breast cancer.
First Author: Elizabeth Joyce
Poster
2017 ASCO Annual Meeting
Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E), or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer: The FATA-GIM3 trial.
First Author: Francesco Perrone
Poster
2023 ASCO Annual Meeting
Influence of ovarian function supression on quality of life in breast cancer survivors during adjuvant endocrine therapy.
First Author: Natalija Dedic Plavetic